You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Merck
Baxter
Dow
Express Scripts

Last Updated: May 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Omarigliptin


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Omarigliptin?

Omarigliptin is an investigational drug.

There have been 15 clinical trials for Omarigliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., British University In Egypt, and [disabled in preview].

There are seventeen US patents protecting this investigational drug and ninety-six international patents.

Recent Clinical Trials for Omarigliptin
TitleSponsorPhase
Omarigliptin in Four Healthy Egyptian VolunteersBritish University In EgyptN/A
Omarigliptin & Trelagliptin in Twelve Healthy Egyptian VolunteersBritish University In EgyptN/A
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)Merck Sharp & Dohme Corp.Phase 4

See all Omarigliptin clinical trials

Clinical Trial Summary for Omarigliptin

Top disease conditions for Omarigliptin
Top clinical trial sponsors for Omarigliptin

See all Omarigliptin clinical trials

US Patents for Omarigliptin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Omarigliptin   Start Trial Process for preparing chiral dipeptidyl peptidase-IV inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Omarigliptin   Start Trial Process for preparing aminotetrahydropyrans F.I.S.--Fabbrica Italiana Sintetici S.p.A. (IT)   Start Trial
Omarigliptin   Start Trial Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Omarigliptin   Start Trial Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Omarigliptin   Start Trial Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Merck Sharpe & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Omarigliptin

Drugname Country Document Number Estimated Expiration Related US Patent
Omarigliptin Japan 2017523172 2034-07-21   Start Trial
Omarigliptin Japan 2019069999 2034-07-21   Start Trial
Omarigliptin Japan 6574474 2034-07-21   Start Trial
Omarigliptin World Intellectual Property Organization (WIPO) 2016014324 2034-07-21   Start Trial
Omarigliptin China 107614496 2035-12-03   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Dow
McKesson
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.